Search Contract Opportunities

Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

ID: HT9402-24-Q-9104 • Type: Solicitation
Question & Answer Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Do the documents mention an incumbent contractor?
Does this contract have any security clearance requirements?
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

The Department of Defense (DoD) is required by law (10 U.S.C. 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: February 2024: The following drug classes/subclass will be reviewed:

a. Augtyro - Oncological Agents Subclass: Lung Cancer
b. Cabtreo - Acne Agents Subclass: Topical Acne And Rosacea
c. Coxanto - Pain Agents Subclass: NSAID
d. Jylamvo - Antirheumatic Subclass: NA
e. Ogsiveo - Oncological Agents Subclass: NA
f. Truqap - Oncological Agents Subclass: Breast Cancer
g. Xalkori - Oncological Agents Subclass: Lung Cancer

The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9104.

Pre-quote teleconference is on January 10, 2024, details are stated in Part 2.5. Pre-quote teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.

Background
The Department of Defense (DoD) is required by law (10 U.S.C. ยง 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF).

Work Details
The Department of Defense is seeking quotes from industry for pharmaceutical agents within Drug Classes identified for placement on the UF. The RFQ includes UF Blanket Purchase Agreements (UF BPA) and UF Additional Discount Program (UF ADP) Appendices. The solicitation outlines specific steps for quote submission, including a pre-quote teleconference, submission deadlines, and points of contact. The solicitation also provides detailed instructions for submitting UF BPA and UF ADP quotes, including requirements for NDC Price Lists and conditions for price changes.

Overview

Response Deadline
Jan. 18, 2024, 1:00 p.m. EST Past Due
Posted
Dec. 21, 2023, 10:00 a.m. EST
Set Aside
None
Place of Performance
San Antonio, TX 78230 United States
Source
SAM

Current SBA Size Standard
1300 Employees
Pricing
Likely Fixed Price
Est. Level of Competition
Average
Vehicle Type
Blanket Purchase Agreement
On 12/21/23 Defense Health Agency issued Solicitation HT9402-24-Q-9104 for Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program due 1/18/24. The opportunity was issued full & open with NAICS 325412 and PSC 6505.
Primary Contact
Name
Tracy Banks   Profile
Phone
None

Secondary Contact

Name
Stephanie Erpelding   Profile
Phone
None

Documents

Posted documents for Solicitation HT9402-24-Q-9104

Question & Answer

Incumbent or Similar Awards

Contracts Similar to Solicitation HT9402-24-Q-9104

Potential Bidders and Partners

Awardees that have won contracts similar to Solicitation HT9402-24-Q-9104

Similar Active Opportunities

Open contract opportunities similar to Solicitation HT9402-24-Q-9104

Additional Details

Source Agency Hierarchy
DEPT OF DEFENSE > DEFENSE HEALTH AGENCY (DHA) > DEFENSE HEALTH AGENCY
FPDS Organization Code
97DH-HT9402
Source Organization Code
100142347
Last Updated
July 18, 2024
Last Updated By
tracy.e.banks2.civ@mail.mil
Archive Date
July 18, 2024